1. NF-κB in the New Era of Cancer Therapy
- Author
-
Véronique Baud, Baptiste Eluard, and Catherine Thieblemont
- Subjects
0301 basic medicine ,Cancer Research ,Energy metabolism ,Cancer therapy ,Genomics ,Bioinformatics ,Immunotherapy, Adoptive ,Oxidative Phosphorylation ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Warburg Effect, Oncologic ,Humans ,Transcription factor ,Immune Checkpoint Inhibitors ,Receptors, Chimeric Antigen ,business.industry ,NF-kappa B ,Cancer ,NF-κB ,medicine.disease ,Immune checkpoint ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Tumor Escape ,business ,Reprogramming ,Signal Transduction - Abstract
Although mortality rates have declined in recent years, the majority of cancers remain incurable and the medical challenge is evident. Recent progress in cancer genetics and genomics along with the identification of a novel generation of cancer hallmarks, that is, reprogramming of energy metabolism and evasion from immune surveillance, have led to the discovery of novel NF-κB-dependent cancer vulnerabilities. These discoveries have led to better patient stratification, and new drug combinations using cutting-edge therapies. This review aims to give an up-to-date view on the therapeutic potential of NF-κB transcription factors and the signaling pathways that control their activity in the new era of cancer therapy.
- Published
- 2020